Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

Publications

  • Eckhardt S, Szántó J, Cerar O, Chylak V, Hernádi Z, Hindy I, József S, Juhos E, Kolaric K, Kopecny J, et al. z 1987;44:69-72.

  • Eckhardt S, Juhos E, Hindy I, Jelic S, Koza I, László G, Mechl Z, Nagykálnay T, Pawlicki M, Schoket Z, et al. Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European Oncology Group Study. Oncology. 1988;45:409-12.

  • Eckhardt S, Hernádi Z, Thurzó L, Telekes A, Sopkova B, Mechl Z, Pawlicki M, Kerpel-Fronius S. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. Oncology. 1990;47:289-95.

  • Eckhardt S, Kolaric K, Vukas D, Kánitz E, Schoket Z, Jassem J, Vuletic L, Jelic S, Mechl Z, Koza I, et al. Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG). Med Oncol Tumor Pharmacother. 1990;7:19-23.

  • Kánitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, Rolski J, Schoket Z, Vukas D, Kaplan E, et al. Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology. 1992;49:327-32.

  • Jassem J, Gyergyay F, Kerpel-Fronius S, Nagykálnai T, Baumöhl J, Verweij J, Vuletic L, Mechl Z, Drozd-Lula M, Jelic S, et al. Combination of daily 4-hour infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma. A South-East European Oncology Group (SEEOG) study. Cancer Chemother Pharmacol, 1993; 31: 489-494.

  • Coombes RC, Hall E, Jassem J, Schoket Z, Krzakowski M: Clinical trials in Central and Eastern Europe: organizational aspects Crit Rev Oncol Hematol  2002, 42, 157-161

  • Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C: Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-92

  • Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM : Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-70.

  • Jassem J. Intergroup : Exemestane Study mature analysis: overall survival data. Anticancer Drugs. 2008, 19, Suppl 1, S3-7.

  • Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Hirsch FR. : ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 20: 689-95, 2009

  • Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, Kowalczyk A, Singh S, Ranger-Moore J, Manriquez G, Gaire F, Jassem J, Hirsch FR.: Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 5:1905-11, 2010

  • Bertelli G, Hall E, Ireland E, Snowdon CF, Jassem J, Drosik K, Karnicka-Mlodkowska H, Coombes RC, Bliss JM : Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol. 2010;21:498-505

  • Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. : Insulin-like growth factor receptor-1 gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between fluorescent in-situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28:2174-80, 2010

  • Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arlukowicz B, Wysocki P, Jankowski T, Radecka B, Foszczynska-Kloda M, Litwiniuk M, Sylwia D, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. http://www.ncbi.nlm.nih.gov/pubmed/22234627 Oncologist. 2012 Jan 10. [Epub ahead of print]

  • Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz M, Wysocki P, Jankowski T, Radecka B, Foszczyńska-Kłoda M, Litwiniuk M, Dębska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Correlation between quantitative HER2 protein expression and risk of brain metastases in HER2-positive advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 2012;17:26-35.
  • <--20120924-->
  • Duchnowska R, Dziadziuszko R, Trojanowski T, Mandat T, Och W, Czartoryska-Arlukowicz B, Radecka B, Olszewski W, Szubstarski F, Kozlowski W, Jarosz B, Rogowski W, Kowalczyk A, Limon J, Biernat W, Jassem J, Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res. 2012 Aug 16;14(4):R119.
  • Minuti G, Cappuzzo F, Duchnowska R, *Jassem J*, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-Garcia M. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012;107:793-9.

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.